Search

Your search keyword '"Ignasi Figueras-Nart"' showing total 18 results
Start Over Author "Ignasi Figueras-Nart" Search Limiters Full Text
18 results on '"Ignasi Figueras-Nart"'

1. Documento de información y consenso para el manejo diagnóstico y terapéutico del prurito asociado a la enfermedad renal crónica en pacientes en hemodiálisis en España

Author

Juan Manuel Buades, Ignasi Figueras-Nart, Marian Goicoechea, Rafael Jesús Sánchez Villanueva, and Esther Serra-Baldrich

Subjects
Pruritus, Chronic kidney failure, Diagnostic, Treatment, Hemodialysis, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Resumen: El prurito asociado a la enfermedad renal crónica (Pa-ERC) es una de las comorbilidades más comunes e incapacitantes en los pacientes con ERC avanzada. Además, está asociado a un mayor riesgo de mortalidad, peor calidad de vida, aparición de trastornos del sueño, alteraciones de la salud mental y mayor uso de recursos sanitarios. La presentación clínica del Pa-ERC es muy heterogénea, lo que dificulta su diagnóstico y su tratamiento. Actualmente, no existen guías a nivel nacional sobre el manejo del Pa-ERC.El objetivo de este documento es proporcionar unas recomendaciones de consenso a nivel nacional para el manejo diagnóstico y terapéutico del Pa-ERC.La elaboración del documento se realizó en tres fases: la realización de una propuesta de algoritmo de manejo diagnóstico y terapéutico por parte de un grupo reducido de especialistas en nefrología; la validación de la propuesta por un grupo más amplio de nefrólogos y, finalmente, una segunda validación por un grupo multidisciplinar en el que se incluyeron, además, especialistas en dermatología.El algoritmo de manejo diagnóstico y terapéutico trata de cubrir la actual necesidad por una falta de directrices específicas para el control adecuado del Pa-ERC en España. A la vez, introduce el uso de difelicefalina, el primer y único fármaco aprobado específicamente para el Pa-ERC de pacientes en hemodiálisis, con un buen perfil de seguridad y eficacia. Abstract: Chronic kidney disease-associated pruritus (CKD-aP) is one of the most common and disabling comorbidities in patients with advanced CKD. In addition, it is associated with an increased risk of mortality, poorer quality of life, sleep disorders, mental health disorders, and increased use of health care resources. The clinical presentation of CKD-aP is very heterogeneous, making it difficult to diagnose and treat. Currently, there are no national guidelines on the management of CKD-aP.The aim of this document is to provide national consensus recommendations for the diagnostic and therapeutic management of CKD-aP.The document was prepared in three phases: a diagnostic and therapeutic management algorithm was proposed by a small group of nephrology specialists; the proposal was validated by a larger group of nephrologists; and a second validation by a multidisciplinary group that also included dermatology specialists.The diagnostic and therapeutic management algorithm attempts to cover the current need of a lack of specific guidelines for the adequate management of CKD-aP. At the same time, it introduces the use of difelikefalin, the first and only drug specifically approved for CKD-aP, with a good safety and efficacy profile.

Published
2024
Full Text
View/download PDF

2. Upadacitinib for prurigo nodularis

Author

Clara Muntaner-Virgili, MD, Carlos Moreno-Vilchez, MD, Clara Torrecilla-Vall-Llossera, MD, and Ignasi Figueras-Nart, MD

Subjects
dupilumab, JAK inhibitor, prurigo, prurigo nodularis, pruritus, upadacitinib, Dermatology, RL1-803
Published
2024
Full Text
View/download PDF

3. Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

Author

Ana Batalla, Hae Jin Suh‐Oh, Gregorio Carretero Hernández, Javier Miquel‐Miquel, Rafael Botella‐Estrada, Antonio Martorell‐Calatayud, Virginia Sanz‐Motilva, Ignasi Figueras‐Nart, and Angeles Flórez

Subjects
atopic dermatitis, treatment, upadacitinib, Dermatology, RL1-803, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the efficacy and safety of upadactinib in clinical practice. Methods An observational and multicentric study was conducted. Inclusion criteria consisted of patients who had previously received upadacitinib in the clinical trial M19‐850 and continued treatment with upadacitinib (15 mg or 30 mg) under daily clinical practice conditions for 12 months. Demographic data, characteristics of AD, treatment response and adverse events were recorded. Preliminary results at 24‐week follow‐up are herein presented. Results A total of 26 patients (61.54% males, mean age: 35.58 years) were included in the study; of these, 92.31% received upadacitinib 30 mg at baseline. At 24 weeks, mean values of Eczema Area and Severity Index and body surface area were 2.26 and 2.37%, respectively, 82.35% of the patients reached the Investigator's Global Assessment 0/1 and the mean value of peak pruritus numerical rating scale was 1.74. Adverse events were present in 19.23% of the cases, causing one definitive treatment interruption (due to herpes zoster) and two temporary treatment discontinuations (due to temporary elevation of creatine kinase). Conclusions These data support the maintenance of the efficacy of upadacitinib at 24‐week posttrial follow‐up, with no unexpected safety concerns. More real‐world data are needed to confirm these results.

Published
2023
Full Text
View/download PDF

4. Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients

Author

Lídia Sans-de San Nicolàs, Ignasi Figueras-Nart, Irene García-Jiménez, Montserrat Bonfill-Ortí, Antonio Guilabert, Laia Curto-Barredo, Marta Bertolín-Colilla, Marta Ferran, Esther Serra-Baldrich, Ramon M. Pujol, and Luis F. Santamaria-Babí

Subjects
atopic dermatitis, CCL27, CLA+ memory T cells, house dust mite, IgE, IL-31, Immunologic diseases. Allergy, RC581-607
Abstract

BackgroundThe role of allergen sensitization in IL-31 production by T cells and specifically in the clinical context of atopic dermatitis (AD) has not been characterized.MethodsThe response to house dust mite (HDM) in purified memory T cells cocultured with epidermal cells from AD patients (n=58) and control subjects (n=11) was evaluated. AD-associated cytokines from culture supernatants, plasma proteins and mRNA expression from cutaneous lesions were assessed and related with the clinical features of the patients.ResultsHDM-induced IL-31 production by memory T cells defined two subsets of AD patients according to the presence or absence of IL-31 response. Patients in the IL-31 producing group showed a more inflammatory profile, and increased HDM-specific (sp) and total IgE levels compared to the IL-31 non-producing group. A correlation between IL-31 production and patient’s pruritus intensity, plasma CCL27 and periostin was detected. When the same patients were analyzed based on sp IgE and total IgE levels, an increased IL-31 in vitro response, as well as type 2 markers in plasma and cutaneous lesions, was found in patients with sp IgE levels > 100 kUA/L and total IgE levels > 1000 kU/L. The IL-31 response by memory T cells was restricted to the cutaneous lymphocyte-associated antigen (CLA)+ T-cell subset.ConclusionIgE sensitization to HDM allows stratifying IL-31 production by memory T cells in AD patients and relating it to particular clinical phenotypes of the disease.

Published
2023
Full Text
View/download PDF

5. Definition of Recurrent Chronic Spontaneous Urticaria

Author

Gemma Melé-Ninot, Esther Serra-Baldrich, Laia Curto-Barredo, Ignasi Figueras-Nart, Jorge Spertino, Vicente Expósito-Serrano, Xavier García-Navarro, Antonio Guilabert, Isabel Bielsa-Marsol, and Ana M. Giménez-Arnau

Subjects
chronic spontaneous urticaria, chronic urticaria, recurrent chronic spontaneous urticaria, Dermatology, RL1-803
Abstract

Abstract is missing (Short communication)

Published
2020
Full Text
View/download PDF

6. Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases

Author

Ignasi Figueras-Nart, José M. Mascaró, Xavier Solanich, and José Hernández-Rodríguez

Subjects
monogenic autoinflammatory diseases, autoinflammatory diseases, clinical dermatology, maculopapular rash, urticarial rash, dermatopathology, Immunologic diseases. Allergy, RC581-607
Abstract

Autoinflammatory diseases include disorders with a monogenic cause and also complex conditions associated to polygenic or multifactorial factors. An increased number of both monogenic and polygenic autoinflammatory conditions have been identified during the last years. Although skin manifestations are often predominant in monogenic autoinflammatory diseases, clinical and histopathological information regarding their dermatological involvement is still scarce. Monogenic autoinflammatory diseases with cutaneous expression can be classified based on the predominant lesion: (1) maculopapular rashes or inflammatory plaques; (2) urticarial rashes; (3) pustular, pyogenic or neutrophilic dermatosis-like rashes; (4) panniculitis or subcutaneous nodules; (5) vasculitis or vasculopathy; (6) hyperkeratotic lesions; (7) hyperpigmented lesions; (8) bullous lesions; and (9) aphthous lesions. By using this classification, this review intends to provide clinical and histopathological knowledge about cutaneous involvement in monogenic autoinflammatory diseases.

Published
2019
Full Text
View/download PDF

7. Mucocutaneous Response to New Therapeutic Strategies in Behçet’s Disease: A Retrospective Cohort Study

Author

Carlos Moreno-Vílchez, Rosa Fornons-Servent, Xavier Solanich, Javier Narvaez, and Ignasi Figueras-Nart

Subjects
Malaltia de Behçet, Behçet's disease, Article Subject, Therapeutics, Dermatology, General Medicine, Terapèutica
Abstract

Mucocutaneous lesions are the most frequent symptoms of Behçet’s disease (BD). Recently, new therapies are being used to treat refractory cases, but the effect of these treatments on mucocutaneous manifestations has been scarcely reported. Our objective was to describe the mucocutaneous response to the different therapies used to treat BD in routine clinical practice. We retrospectively reviewed the clinical records of all patients diagnosed with BD seen at our institution between January 2010 and January 2022. Patients with BD without mucocutaneous manifestations were excluded. We included 109 patients diagnosed with BD: 51 males (46.8%) and 58 females (53.2%). The mean age at diagnosis was 31.58 years (standard deviation (SD) 12.110) and the mean time of disease evolution was 14.94 years (SD 11.094). Oral ulcers were the most frequent symptom present in 100% of patients, followed by genital ulcers (GU) in 76.1% of patients. Twenty-four patients (22%) had severe mucocutaneous symptoms (>12 lesions/year) before treatment. We found that among patients with GU there was a higher prevalence of episodes of posterior uveitis and venous thrombosis ( p = 0.011 and p = 0.045 , respectively). In our series, we observed a lower complete cutaneous response to colchicine in patients with GU, pathergy or severe mucocutaneous symptoms ( p < 0.05 ). Regarding the choice of a TNF-α inhibitor, we observed a lower prevalence of complete cutaneous response to adalimumab among patients with GU (53.3% complete response in patients with GU vs. 100% in patients without GU, p = 0.022 ), whereas no differences were found between clinical characteristics in the response to infliximab.

Published
2023
Full Text
View/download PDF

8. Frontal fibrosing alopecia in men: A multicenter study of 39 patients

Author

Andrea Combalia, Ignasi Figueras-Nart, Ramon Grimalt, María Librada Porriño-Bustamante, Virginia Velasco-Tamariz, Juan Francisco Mir-Bonafé, Ramon M. Pujol, Enrique Rodríguez-Lomba, Alejandro Lobato-Berezo, and Maribel Iglesias-Sancho

Subjects
Male, medicine.medical_specialty, business.industry, Frontal fibrosing alopecia, Lichen Planus, Alopecia, Dermatology, Scarring alopecia, medicine.disease, Lichen planopilaris, Fibrosis, Hair loss, Multicenter study, medicine, Humans, business
Published
2022
Full Text
View/download PDF

9. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis

Author

Lídia Sans‐De San Nicolàs, Ignasi Figueras‐Nart, Montserrat Bonfill‐Ortí, Carmen De Jesús‐Gil, Irene García‐Jiménez, Antonio Guilabert, Laia Curto‐Barredo, Marta Bertolín‐Colilla, Marta Ferran, Esther Serra‐Baldrich, Anna Zalewska‐Janowska, Yui‐Hsi Wang, Michael D. Howell, Ramon M. Pujol, Luis F. Santamaria‐Babí, [Sans-De San Nicolàs L, De Jesús-Gil C, García-Jiménez I] Grup d’Immunologia Translacional, Departament de Biologia Cel·lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, Spain. [Figueras-Nart I, Bonfill-Ortí M] Departament de Dermatologia, Hospital de Bellvitge, Universitat de Barcelona (UB), L’Hospitalet de Llobregat, Spain. [Guilabert A] Departament de Dermatologia, Hospital General de Granollers, Granollers, Spain, and Hospital General de Granollers

Subjects
Estafilococs daurats, enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::dermatitis::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::enfermedades de la piel y tejido conjuntivo::enfermedades de la piel::dermatitis atópica [ENFERMEDADES], Bacteria::Bacteria::Firmicutes::Bacillales::Staphylococcaceae::Staphylococcus::Bacteria::Bacteria::Staphylococcus aureus [ORGANISMS], Estafilococs, Pell--Malalties, Immunology, Skin and Connective Tissue Diseases::Skin Diseases::Dermatitis::Skin and Connective Tissue Diseases::Skin Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Dermatitis, Atopic [DISEASES], Immunology and Allergy, Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes [ANATOMY], Pell - Infeccions, Dermatitis atòpica, Bacteria::Bacteria::Firmicutes::Bacillales::Staphylococcaceae::Staphylococcus::Bacteria::Bacteria::Staphylococcus aureus [ORGANISMOS], células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T [ANATOMÍA]
Abstract

Atopic dermatitis; Cutaneous lymphocyte antigen; Skin infections Dermatitis atópica; Antígeno cutáneo de linfocitos; Infecciones de la piel Dermatitis atòpica; Antigen limfòcit cutani; Infeccions de la pell Staphylococcus aureus, memory skin-homing cutaneous lymphocyte-associated antigen (CLA)+ T cells and IL-13 constitute relevant play-ers in atopic dermatitis (AD) pathogenesis.1 Since circulating CLA+ T cells reflect cutaneous abnormalities present in human inflammatory skin diseases,2 an ex vivo coculture model made of purified circu-lating CLA+/− effector and central memory T cells and autologous lesional epidermal cells was established. We show a CLA-dependent production of IL-13 upon activation with staphylococcal enterotoxin B (SEB) that allows the differentiation of the Th2 high and Th2 low groups, with distinct clinical correlations between both groups, within a clinically homogeneous population of adult non-treated moderate-to- severe AD patients.

Published
2022

10. Recomendaciones del Grupo Español de Investigación en Dermatitis de Contacto y Alergia Cutánea (GEIDAC) de la AEDV en relación con la realización de pruebas epicutáneas durante la pandemia por SARS-CoV-2 (COVID-19)

Author

J.M. Carrascosa, M.A. Pastor-Nieto, I. Ruiz-González, J.F. Silvestre, L. Borrego, M.E. Gatica-Ortega, A.M. Giménez-Arnau, José Carlos Armario Hita, Leopoldo Borrego Hernando, José Manuel Carrascosa Carrillo, Susana Córdoba Guijarro, Laia Curto, Virginia Fernández Redondo, Ignasi Figueras Nart, Juan García Gavín, María Elena Gatica Ortega, Anna Giménez Arnau, Elena Giménez Arnau, Enrique Gómez de la Fuente, Ricardo González Pérez, Felipe Heras Mendaza, Marcos Hervella Garcés, Pilar Manrique Martínez, Pedro Mercader García, Francisco Javier Ortiz de Frutos, Javier Miquel Miquel, María Antonia Pastor Nieto, Mercedes Rodríguez Serna, Inmaculada Ruíz González, Araceli Sánchez Gilo, Paloma Sánchez-Pedreño Guillén, Javier Sánchez Pérez, Tatiana Sanz Sánchez, Esther Serra-Baldrich, Juan Francisco Silvestre Salvador, and Violeta Zaragoza Ninet

Subjects
Histology, epicutáneas, Contact, contacto, COVID-19, Dermatitis, General Medicine, telemedicine, Dermatology, Article, Patch testing, Pathology and Forensic Medicine
Abstract

Resumen Con el progresivo control de la pandemia por SARS-CoV-2, los miembros del Grupo Espanol de Investigacion en Dermatitis de Contacto y Alergia Cutanea (GEIDAC) realizan una propuesta sobre cuales van a ser los requisitos, las limitaciones y los condicionantes para reanudar el servicio en las unidades de dermatitis de contacto en un escenario en el que se presume la persistencia del virus, con episodios ocasionales o estacionales de exacerbacion. Se aconseja ajustar el numero de pruebas epicutaneas (PE) a las posibilidades de cada centro y la revision de los casos en lista de espera para priorizar a los pacientes en funcion de la gravedad y la urgencia. Se ofreceran, si es factible, metodos telematicos para los documentos relativos a las PE (informacion, pautas, documentos de consentimiento informado). De estar disponible, puede ofrecerse la opcion de realizar una primera visita telematica. Igualmente, en pacientes seleccionados puede llevarse a cabo una televisita en las visitas de lectura a traves de imagenes realizadas por el paciente o mediante una videovisita que permita visualizar el resultado de la exploracion. Estas acciones permitiran reducir el numero de visitas presenciales, aunque no el tiempo dedicado y asignado al facultativo para los actos medicos. Todas estas recomendaciones son sugerencias y se adaptaran a los requisitos y a las posibilidades de cada centro sanitario

Published
2020
Full Text
View/download PDF

11. Definition of Recurrent Chronic Spontaneous Urticaria

Author

E Serra-Baldrich, Xavier García-Navarro, Antonio Guilabert, Gemma Melé-Ninot, Vicente Expósito-Serrano, Ignasi Figueras-Nart, J. Spertino, Isabel Bielsa-Marsol, Laia Curto-Barredo, and Ana Giménez-Arnau

Subjects
chronic urticaria, medicine.medical_specialty, Hardware_MEMORYSTRUCTURES, Urticaria, business.industry, recurrent chronic spontaneous urticaria, MEDLINE, Dermatology, General Medicine, Omalizumab, lcsh:RL1-803, Chronic Disease, lcsh:Dermatology, Medicine, Humans, chronic spontaneous urticaria, Chronic Urticaria, business, Urticària, Chronic urticaria
Abstract

is missing (Short communication)

Published
2020

12. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence

Author

Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine

Subjects
medicine.medical_specialty, Edema angioneuròtic, Urticaria, media_common.quotation_subject, Immunology, education, GA2LEN, Angioedema, Center, Excellence, Management, urticaria, centres of reference and excelence, immune system diseases, center, medicine, Immunology and Allergy, Center (algebra and category theory), Angioneurotic edema, skin and connective tissue diseases, media_common, udc:616.1, business.industry, angioedema, humanities, referenčni centri odličnosti, Medicine, Allergy, Family medicine, excellence, medicine.symptom, business, Global Allergy and Asthma European Network, Urticària, management
Abstract

This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.

Published
2020
Full Text
View/download PDF

13. Atopic Dermatitis: From Physiopathology to the Clinics

Author

Oscar Palomares-Gracia and Ignasi Figueras-Nart

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, InformationSystems_INFORMATIONSTORAGEANDRETRIEVAL, Atopic dermatitis, medicine.disease, Dermatology, Pathophysiology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine, business, GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Atopic dermatitis is a chronic, pruritic, relapsing inflammatory disease with a complex etiopathogenesis. Alterations of the epidermal barrier function together with a predominantly type 2 altered immune response are responsible for the heterogeneous clinical manifestation. Although pruritic eczematous plaques represent the most frequent phenotype, several others are also characteristic. The diagnostic of the disease relies on clinical aspects, and no complimentary tests are needed. In the literature, we can find a significant number of diagnostic and screening biomarkers; however, severity ones are the most reliable and applicable. Patient-tailored treatment is mandatory, as not all the patients equally respond to the same drugs. The newly released therapies, as well as those under investigation, give hope to AD patients.

Published
2019

14. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series

Author

Joaquín Sastre, Antonio Valero, J.F. Silvestre, Ricardo Ruiz-Villaverde, P. Herranz‐Pinto, José Juan Pereyra-Rodríguez, Laia Curto-Barredo, Leandro Martinez-Pilar, F.J. Ortiz‐de‐Frutos, L. Herraez‐Herrera, Ignasi Figueras-Nart, E Serra-Baldrich, I. Jáuregui‐Presa, J.C. Armario-Hita, and R. Izu‐Belloso

Subjects
Moderate to severe, Adult, Male, medicine.medical_specialty, Adolescent, Dermatology, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Dermatitis, Atopic, Young Adult, Quality of life, Severity of illness, medicine, Humans, Young adult, Aged, Retrospective Studies, business.industry, Pruritus, Retrospective cohort study, Atopic dermatitis, Middle Aged, medicine.disease, Conjunctivitis, Dupilumab, Clinical Practice, Treatment Outcome, Quality of Life, Female, business, Follow-Up Studies
Published
2019

15. Langerhans cell histiocytosis presenting as fingernail changes

Author

Asunción Vicente, Cristina Jou-Muñoz, Julia María Sánchez-Schmidt, Ofelia Cruz-Martinez, Ignasi Figueras-Nart, Veronica Paola Celis-Passini, Maria Antonia González-Ensenyat, and Xavier Bordas-Orpinell

Subjects
medicine.medical_specialty, business.industry, Mortality rate, Langerhans cell histiocytosis, Case Report, Dermatology, Disease, Prognostic factors, medicine.disease, Multisystem disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Nail (anatomy), medicine, Ungles -- Malalties, LCH, Langerhans cell histiocytosis, Nail involvement, business
Abstract

Langerhans cell histiocytosis (LCH) identifies a spectrum of disorders that are classified according to the organs involved (single- or multi-organ disease) and the presence or absence of organ failure. Patients younger than 2 years with a multisystem disease have a significantly higher mortality rate than older children.1 Nail involvement in LCH is extremely uncommon and rarely reported. To our knowledge, 18 cases have been documented in the literature to date. According to most cases reported, it is thought to indicate a poor prognosis.2, 3, 4, 5, 6 We report the case of a child with nail lesions, which led to a diagnosis of LCH.

Published
2016
Full Text
View/download PDF

16. Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria

Author

N Lamas-Domenech, M Villar, Xavier Cubiró, E Serra-Baldrich, Vicente Expósito-Serrano, C Baliu-Piqué, Laia Curto-Barredo, Gemma Melé-Ninot, X Duran-Jordà, M. Bonfill-Ortí, J. Spertino, I Bielsa-Marsol, G Aparicio, X García-Navarro, A Álvarez, Ana Giménez-Arnau, M. Vilavella, A. Guilabert, J Garcias-Ladaria, and Ignasi Figueras-Nart

Subjects
Adult, medicine.medical_specialty, Urticaria, Treatment outcome, Drug Resistance, Dermatology, Omalizumab, Disease activity, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Refractory, Anti-Allergic Agents, Medicine, Humans, In patient, Retrospective Studies, Dose-Response Relationship, Drug, business.industry, Urticària -- Tractament, Age Factors, Retrospective cohort study, Middle Aged, Treatment Outcome, 030228 respiratory system, Multicenter study, Chronic Disease, Female, business, medicine.drug
Published
2018

17. Actinic Keratosis, a Chronic, Progressive Disease: Understanding Clinical Gaps to Optimise Patient Management

Author

Rino Cerio, Ignasi Figueras Nart, Thomas Dirschka, Giovanni Pellacani, Brigitte Dréno, Andrés Ruiz de Casas, John T. Lear, and Ketty Peris

Subjects
0301 basic medicine, 030103 biophysics, medicine.medical_specialty, Consensus, Skin Neoplasms, Keratosis, Treatment outcome, MEDLINE, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Risk Factors, Severity of illness, lcsh:Dermatology, actinic keratosis, Medicine, Humans, Tumors, integumentary system, business.industry, Actinic keratosis, General Medicine, lcsh:RL1-803, medicine.disease, Professional Practice Gaps, Patient management, Skin diseases, Keratosis, Actinic, Treatment Outcome, Malalties de la pell, Predictive value of tests, Chronic Disease, Practice Guidelines as Topic, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Progressive disease
Abstract

Actinic keratosis (AK) is a chronic, progressive disease of the skin that has undergone long-term sun exposure. The affected areas contain visible and subclinical nonvisible sun damage resulting in epidermal keratinocyte dysplasia, known by many as ‘field cancerisation’ (1), which is prone to AKs and sun-related skin cancer (2). Thus, visible AKs are clinical biomarkers for a photo-damaged field with subclinical damage associated with the unpredictable risk of progression to invasive squamous cell carcinoma (iSCC) (3). The aim of this multiexpert opinion article is to provide a discussion succinctly highlighting the clinical gaps for optimal management of AK: the lack of a universal definition and the need for a standardised grade assessment of AK/field cancerisation that also takes into account individual risk.

Published
2017

18. A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity

Author

Brigitte Dréno, Rino Cerio, Thomas Dirschka, Ignasi Figueras Nart, John T. Lear, Ketty Peris, Andrés Ruiz de Casas, Shaniko Kaleci, and Giovanni Pellacani

Subjects
actinickeratosis, fieldcancerization, gradingscale, Dermatology, RL1-803
Abstract

Actinic keratosis (AK) lesions are surrounded by field cancerization (areas of subclinical, non-visible sun damage). Existing AK grading tools rely on AK counts, which are not reproducible. An Actinic Keratosis Field Assessment Scale (AK-FAS) for grading the severity of AK/field was developed. Standardized photographs of patients representing the full range of AK severity were collected. Six investigators independently rated each photograph according to 3 criteria: AK area (total skin area affected by AK lesions), hyperkeratosis and sun damage. Inter-rater reproducibility was good for all 3 criteria. Validation of the AK-FAS showed good reproducibility for AK area and hyperkeratosis, even for dermatologists untrained on use of the scale. In conclusion, the AK-FAS is objective, easy to use and implement, and reproducible. It incorporates assessment of the entire field affected by AK instead of relying on lesion counts. Use of the AK-FAS may standardize AK diagnosis, making it relevant to routine clinical practice

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results